NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,234.57 +33.30 (+0.19%) CRUDE OIL
82.98 +0.17 (+0.21%) GOLD FUTURES
2,331.00 -7.40 (-0.32%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,524.38 -1,823.71 (-3.42%)
Dr. Reddy's Laboratories Limited (RDY)
After hours:
| Previous close | 71.49 |
| Open | 71.43 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's range | 70.78 - 71.63 |
| 52-week range | 53.12 - 77.72 |
| Volume | |
| Avg. volume | 191,262 |
| Market cap | 11.9B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 18.86 |
| EPS (TTM) | 3.76 |
| Earnings date | N/A |
| Forward dividend & yield | 0.49 (0.69%) |
| Ex-dividend date | 07 Jul 2023 |
| 1y target est | 80.06 |
GlobeNewswirePharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
Business WireDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
ZacksWhy Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
